Press "Enter" to skip to content

FDA expands approval of treatment for cystic fibrosis to include patients ages 6 and older

FDA expanded the indication for Symdeko for treatment of pediatric patients ages 6 years and older with cystic fibrosis who have certain genetic mutations.

Original source:

Also Read:   Coronavirus (COVID-19) Update: Daily Roundup October 6, 2020